Clinical Research

 
Stock Quotes for Clinical Research top ^
  • Industry: Business Services
  • Sector: Industrials
Sign-up for vmcs investment picks

 
News Articles for Clinical Research top ^
VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its clinical programs were presented at the 17 th Annual Meeting of the American Society of Gene and Cell Therapy, which is taking place in in Washington, DC, May 21 to 24.
Sign-up for Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs investment picks
Clinic Will Feature State-of-the-Art Digital Technology and Enhance Access to Oral Health Care for the Underserved MELVILLE, N.Y. , May 14, 2014 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC) , the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, in partnership with Meharry Medical College School of Dentistry, announced today the unveiling and dedication of the Henry Schein Cares Graduate Programs Residency Clinic.
Sign-up for Henry Schein Announces The Unveiling And Dedication Of The Henry Schein Cares Graduate Programs Residency Clinic At Meharry Medical College School Of Dentistry investment picks
SAN DIEGO , May 14, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) , a developer of cell-free molecular diagnostics, today announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku , M.D., Ph.D., of The University of Texas MD Anderson Cancer, has been accepted for publication in 2014 ASCO Annual Meeting Proceedings , a Journal of Clinical Oncology.
Sign-up for Trovagene Announces Data Presentations, Published Abstracts at Annual Meeting of American Society of Clinical Oncology investment picks
ROCKVILLE, Md., April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will present pre-clinical data on its novel DART® candidate for the treatment of autoimmune disorders, MGD010, at IMMUNOLOGY 2014, the American Association of Immunologists Annual Meeting, in Pittsburgh, PA.
Sign-up for MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014 investment picks
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory requirements, the Company plans to submit, during the third quarter of this year, a European marketing application for RHB-102 for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients RHB-102 is a proprietary, once-daily, extended release oral pill formulation of the anti-emetic oncology support drug ondansetron RedHill is also pursuing a new undisclosed indication for RHB-102, which may significantly expand its potential market, with a Phase III study planned to commence in the U.S. later this year TEL-AVIV, Israel, April 30, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
Sign-up for RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014 investment picks
ROCKVILLE, Md., May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART®) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders.
Sign-up for MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014 investment picks
NORTHBROOK, Ill., May 14, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH) , a company enhancing medicine through targeted molecular diagnostics, today announced that six studies performed by various U.S. and international medical facilities have been presented at the 24 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) this week.
Sign-up for Studies Presented at ECCMID 2014 Highlight Accuracy and Potential Clinical Utility of Several Nanosphere Infectious Disease Tests investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1115678&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Threshold Announces Clinical Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2014 investment picks
2014/5/23
SHANGHAI , May 23, 2014 /PRNewswire/ -- Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX) , a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States , today announced a strategic biomarker collaboration.
Sign-up for Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China investment picks
Clinical collaboration with CVS/pharmacy and MinuteClinic will increase access to care and help improve medication adherence for patients WOONSOCKET, R.I. , May 15, 2014 /PRNewswire/ -- CVS Caremark (NYSE: CVS) announced today it has entered into new clinical affiliations with four major regional health systems to enhance access to high-quality, affordable health care services for patients.
Sign-up for CVS Caremark Announces New Clinical Affiliations with Four Major Regional Health Systems investment picks
Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection SAN DIEGO , May 20, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) , a developer of cell-free molecular diagnostics, today announced that data published from ongoing clinical validation studies demonstrate that the company's precision cancer monitoring technology is suitable to non-invasively determine oncogene mutation status in patients with malignant disease.
Sign-up for Trovagene Announces Publication of Data from Clinical Validation Program Using Its Precision Cancer Monitoring Platform investment picks
2014/5/12
ROCKVILLE, Md.
Sign-up for Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update investment picks
HAMPTON, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago.
Sign-up for Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014 investment picks
PORTLAND, Ore., May 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Company's Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50 th Annual Meeting.
Sign-up for Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting investment picks
NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) , a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has completed the enrollment of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration ("wet-AMD"). The study has enrolled a total of 142 patients, and the Company expects to announce interim data on the first 60 patients completing the protocol in June this year.
Sign-up for Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD investment picks
VANCOUVER, British Columbia, April 28, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) presented new clinical data for patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology.
Sign-up for Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02) investment picks
2014/4/28
First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 volunteers from Asia  Initial safety data are consistent with the good safety profile observed in previous studies   LYON, France, April 28, 2014 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the first of two pivotal Phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint.
Sign-up for The World's First, Large-Scale Dengue Vaccine Efficacy Study Successfully Achieved Its Primary Clinical Endpoint investment picks
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - NEW HAVEN, Conn., April 30, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that is has begun dosing study participants with ACH-3422, Achillion's proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial.
Sign-up for Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Client Companies  |  Next: Close Acquisitions